Ankur vaidya

Employment

• UPUMS, Saifai Asst. Professor
  2015 - Present

Education

• Dr. H.S. Gour University Sagar Dr.
  2000 - Present

Projects & Funding

Projects & funding information is unavailable.

Publications (58)

• Stem Cell-Derived Exosomes for Diabetic Wound Healing: Mechanisms, Nano-Delivery Systems, and Translational Perspectives
  Journal of Nanotheranostics 2026 DOI: 10.3390/jnt7010001
  +Save
• Anticancer mechanisms of β‐carbolines
  Chemical Biology & Drug Design 2024 DOI: 10.1111/cbdd.14521
  +Save
• p38 mitogen-activated protein kinase inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00011-5
  +Save
• p21-Activated kinase 1 inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00010-3
  +Save
• Vascular endothelial growth factor receptors (VEGFR/PDGFR) inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00017-6
  +Save
• Tumor necrosis factor receptor–associated protein 1 (TRAP1) inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00016-4
  +Save
• Tubulin polymerization inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00015-2
  +Save
• Serine/threonine-protein kinase B-Raf inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00014-0
  +Save
• Recent updates on c-Src kinase and Src-Abl nonreceptor tyrosine kinases inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00005-x
  +Save
• Rearranged during transfection (RET) inhibitors
  Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy 2024 DOI: 10.1016/b978-0-323-96121-9.00013-9
  +Save